<?xml version="1.0" encoding="UTF-8"?><ns2:project xmlns:ns1="http://gtr.rcuk.ac.uk/gtr/api" xmlns:ns2="http://gtr.rcuk.ac.uk/gtr/api/project" xmlns:ns3="http://gtr.rcuk.ac.uk/gtr/api/fund" xmlns:ns4="http://gtr.rcuk.ac.uk/gtr/api/person" xmlns:ns5="http://gtr.rcuk.ac.uk/gtr/api/project/outcome" xmlns:ns6="http://gtr.rcuk.ac.uk/gtr/api/organisation" ns1:created="2026-06-03T15:52:43Z" ns1:href="http://gtr.ukri.org/gtr/api/projects/CA391944-04EB-420B-9F3A-C74A3F7F3E3B" ns1:id="CA391944-04EB-420B-9F3A-C74A3F7F3E3B"><ns1:links><ns1:link ns1:href="http://gtr.ukri.org/gtr/api/persons/E2DC2709-415D-46DE-8D31-3DF70D4E54EC" ns1:rel="PM_PER"/><ns1:link ns1:href="http://gtr.ukri.org/gtr/api/organisations/82D11B5F-9DED-4863-81EA-18AF49E70380" ns1:rel="LEAD_ORG"/><ns1:link ns1:href="http://gtr.ukri.org/gtr/api/organisations/82D11B5F-9DED-4863-81EA-18AF49E70380" ns1:rel="PARTICIPANT_ORG"/><ns1:link ns1:end="2025-04-29T23:00:00Z" ns1:href="http://gtr.ukri.org/gtr/api/funds/53492E96-C7C3-48C8-9466-28B31BCD9F9A" ns1:rel="FUND" ns1:start="2023-11-01T00:00:00Z"/></ns1:links><ns2:identifiers><ns2:identifier ns2:type="RCUK">10077100</ns2:identifier></ns2:identifiers><ns2:title>GitLife 2.0: Utilising next generation digital technologies to deliver twenty-fold improvement to a unique version control system, enabling SynBio innovations in net zero and healthcare.</ns2:title><ns2:status>Closed</ns2:status><ns2:grantCategory>Investment Accelerator</ns2:grantCategory><ns2:leadFunder>Innovate UK</ns2:leadFunder><ns2:abstractText>Synthetic Biology (SynBio) is the application of engineering principles to biology. Synthetic Biologists think of proteins as machines, composed of multiple different components, each encoded by genes or parts of genes. By rearranging genes, they can make proteins with new functions. SynBio also uses computer modelling heavily, mapping what genes should go where in designs for new biological machine. SynBio aims to solve problems in energy, food production and human health by optimising biological machines. 

Lots of grant funding and private investment has poured into SynBio research. However, there are no reliable systems to match engineered organisms with records of how they were constructed. Because commercial competitors can copy engineered organisms relatively easily, many new ideas fail to be commercialised. It is also critical that companies using SynBio can provide government agencies who regulate SynBio with absolute proof that they are using the strain they say they are.

GitLife Biotech (GLB) has developed a system that can insert 'barcode' sequences of DNA into an organism's genome. Anyone can find out the sequence of this barcode and use it to see what a particular strain is. In this project, they want to make this system more secure by using a computer coding system called Elliptical Curve cryptography. They also want to demonstrate that they can insert several barcodes into a strain at different locations. The DNA sequence of these barcodes, combined with their location makes it practically impossible for anyone wanting to copy the strain to remove these identification marks.

GLB plans to launch this system onto the market in late 2023\. An investment company called SFC Capital are interested in making an equity investment, provided that GLB can secure a grant to cover some of the costs of making their technology more secure and faster to apply.</ns2:abstractText></ns2:project>